摘要
目的:探究不同剂量的米非司酮联合去氧孕烯炔雌醇对治疗围绝经期功能失调性子宫出血的临床疗效。方法:选取本院2014-2017年收治的围绝经期功能失调性子宫出血患者153例,按照随机数字表法将其分为A、B、C组,各51例。A组给予5 mg米非司酮+去氧孕烯炔雌醇治疗,B组给予10 mg米非司酮+去氧孕烯炔雌醇治疗,C组给予15 mg米非司酮+去氧孕烯炔雌醇治疗,比较三组临床疗效,子宫内膜厚度,血红蛋白水平(Hb),性激素[促卵泡刺激素(FSH)、促黄体生成素(LH)、雌二醇(E2)、孕酮(P)]水平,控制出血时间以及完全止血时间,不良反应发生情况等。结果:C组治疗有效率(94.12%)与B组(90.19%)均高于A组(70.58%),差异均有统计学意义(P<0.05);治疗后,三组的FSH、LH、E2及P水平均有所降低,B、C组较A组更为显著,差异均有统计学意义(P<0.05);三组子宫内膜厚度均有所减少,血红蛋白水平均有所升高,C组子宫内膜厚度及血红蛋白水平的改善较A、B组更加显著,差异均有统计学意义(P<0.05);B组不良反应发生率(7.84%)低于A组(9.80%)和C组(11.76%),差异均有统计学意义(P<0.05)。结论:15 mg米非司酮联合去氧孕烯炔雌醇治疗围绝经期功能失调性子宫出血临床疗效更加显著,在临床上可优先使用。
Objective：To investigate the clinical effect of different doses of Mifepristone combined with Desogestrel Ethinylestradiol in the treatment of perimenopausal dysfunction uterine bleeding.Method：53 cases of perimenopausal dysfunctional uterine bleeding were selected in the hospital from 2014 to 2017,according to the random number table method,they were divided into A,B and C group,51 cases in each group.A group was given 5 mg of Mifepristone＋Desogestrel Ethinylestradiol,B group was given 10 mg of Mifepristone＋Desogestrel Ethinylestradiol,C group was given 15 mg of Mifepristone＋Desogestrel Ethinylestradiol,the clinical curative effect,endometrial thickness,hemoglobin（Hb）,the sex hormones of follicle-stimulating hormone（FSH）,luteinizing hormone（LH）,estradiol（E2）and progesterone（P）,control the bleeding time and complete hemostasis time,adverse reactions occur were compared among three groups.Result：The effective rate of treatment in C group（94.12%） and B group（90.19%） were significantly higher than those of A group（70.58%）,the differences were statistically significant（P0.05）.After treatment,FSH,LH,E2 and P levels of three groups were decreased,B group and C group were more significant than those of A group,the differences were statistically significant（P0.05）.The endometrium thickness of three groups were decreased,the hemoglobin levels were increased,and the endometrial thickness and hemoglobin levels in C group improved more significantly than those of A group and B group（P0.05）.The incidence of adverse events in B group（7.84%） was significantly lower than that of A group（9.80%） and C group（11.76%）,the differences were statistically significant（P0.05）.Conclusion：The clinical efficacy of 15 mg Mifepristone combined with Desogestrel Ethinylestradiol in the treatment of perimenopausal dysfunctional uterine bleeding is more remarkable and can be given priority in clinical practice.
出处
《中国医学创新》
CAS
2017年第29期53-57,共5页
Medical Innovation of China
